Hassard James 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Mar 6, 2024
Insider Transaction Report
Form 4
Hassard James
Chief Commercial Officer
Transactions
- Award
Common Stock
2024-03-04+17,000→ 31,000 total - Award
Stock Option (right to buy)
2024-03-04+63,000→ 63,000 totalExercise: $43.51Exp: 2034-03-03→ Common Stock (63,000 underlying)
Footnotes (2)
- [F1]The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2025.
- [F2]The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 4, 2024.